26,000 Shares in Mineralys Therapeutics, Inc. $MLYS Acquired by CenterBook Partners LP

CenterBook Partners LP acquired a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 26,000 shares of the company’s stock, valued at approximately $944,000.

Several other large investors also recently added to or reduced their stakes in the company. RA Capital Management L.P. lifted its holdings in shares of Mineralys Therapeutics by 19.1% in the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after purchasing an additional 1,176,470 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Mineralys Therapeutics by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company’s stock worth $121,676,000 after buying an additional 333,881 shares during the period. Caligan Partners LP grew its holdings in shares of Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock valued at $105,139,000 after buying an additional 755,302 shares in the last quarter. Suvretta Capital Management LLC grew its holdings in shares of Mineralys Therapeutics by 22.2% during the third quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company’s stock valued at $80,850,000 after buying an additional 387,641 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Mineralys Therapeutics by 0.3% during the third quarter. Franklin Resources Inc. now owns 1,809,768 shares of the company’s stock valued at $68,626,000 after buying an additional 6,171 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Down 1.7%

Shares of MLYS stock opened at $23.76 on Thursday. The company has a market capitalization of $1.96 billion, a P/E ratio of -11.59 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 12-month low of $12.59 and a 12-month high of $47.65. The firm has a 50-day moving average price of $27.94 and a 200 day moving average price of $30.78.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. As a group, research analysts expect that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Insider Activity at Mineralys Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 310,700 shares of the firm’s stock in a transaction dated Friday, March 27th. The shares were acquired at an average cost of $23.67 per share, with a total value of $7,354,269.00. Following the completion of the purchase, the director directly owned 5,767,221 shares of the company’s stock, valued at $136,510,121.07. This trade represents a 5.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Malcom Rodman sold 14,058 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08. Following the completion of the transaction, the insider owned 76,140 shares of the company’s stock, valued at $1,999,436.40. This trade represents a 15.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 153,772 shares of company stock valued at $4,121,668 over the last ninety days. Company insiders own 18.94% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. TD Cowen began coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Finally, Bank of America boosted their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Mineralys Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.